Validate predictive biomarkers in breast cancer

1. Gene symbol

 

2. Response

Pathological complete response (n=1775)

Relapse-free survival at 5 years (n=1329)

3. Treatment

Endocrine therapy

Any

Tamoxifen

Aromatase inhibitor

Anti-HER2 therapy

Any

Trastuzumab

Lapatinib

Chemotherapy

Any

Taxane

Anthracycline

Ixabepilone

CMF

FAC

FEC

Total: 0

Non-responders: 0

Responders: 0

4. Filters (optional)

Grade All 1 (n = 112) 2 (n = 632) 3 (n = 974)

Nodal status All Negative (n = 831) Positive (n = 1090)

ER status All Negative (n = 929) Positive (n = 2175)

HER2 status All Negative (n = 2540) Positive (n = 564)

Molecular subtype All TNBC (n = 658) Luminal A (n = 1272) Luminal B (n = 904) HER2+ER- (n = 270)

5. Settings

JetSet only

No outliers

Show quartiles

Multi-gene analysis

Clinical trials

Calculate

By using the services, you agree to be bound by the Terms of Use.

Please kindly cite our paper to support further development: Fekete J & Gyorffy B: ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients, Int J Cancer, 2019 Dec 1;145(11):3140-3151., doi: 10.1002/ijc.32369.